Newron Pharmaceuticals S.p.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stefan Weber
- Full Time Employees
- 22
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Via Antonio Meucci 3 Bresso MI Italy 20091
- IPO Date
- Aug 30, 2017
- Website
- newron.com
- Similar Companies
- Business
- Newron Pharmaceuticals S.p.A. is a biopharmaceutical company specializing in the development of innovative therapies for central nervous system (CNS) disorders, with a primary focus on treatment-resistant schizophrenia (TRS). The company’s main product is evenamide, a first-in-class glutamate modulator designed as an add-on therapy to existing antipsychotics targeting patients with TRS and poorly responding schizophrenia patients. Evenamide is currently in pivotal Phase III clinical development, supported by positive data demonstrating significant and increasing efficacy and a favorable safety profile. Newron also generates royalty income from Xadago, a drug marketed for Parkinson’s disease. The company operates primarily in Europe, the US, and select Asian markets, including Japan and South Korea, through strategic licensing and partnerships. Newron has recently secured major licensing agreements that represent significant developments in its business expansion. In late 2024, the company entered into a license agreement with EA Pharma (a subsidiary of Eisai) to develop, manufacture, and commercialize evenamide in Japan and certain other Asian territories, involving upfront payments, milestone payments, and royalties. Following this, in early 2025, Newron formed a strategic partnership with South Korean pharmaceutical company Myung In Pharm for the development and commercialization of evenamide in South Korea. Myung In Pharm will contribute patients and cover costs for Newron’s pivotal Phase III trial and take responsibility for regulatory and commercialization activities in the region. These partnerships underpin Newron’s global development strategy for evenamide and support its upcoming Phase III ENIGMA-TRS program, which received regulatory approval in 2025 and commenced patient enrollment, including sites in the US, Europe, and Asia. Founded in 2000 and headquartered in Bresso near Milan, Italy, Newron operates within the pharmaceutical industry focusing on CNS and neuropsychiatric disorders. The company’s business model includes research and development of novel drug candidates in schizophrenia and other related disorders, licensing, and commercialization through partners. Key recent operational highlights include the initiation of a randomized, double-blind, one-year Phase III trial planned for 2025, with expected completion and subsequent regulatory filings in major global markets by late 2026. Newron aims to leverage its financial position, bolstered by licensing revenues and funding arrangements, to advance development programs and expand the reach of evenamide worldwide. The company also has a leadership team strengthening corporate governance to support these growth objectives. This comprehensive focus positions Newron Pharmaceuticals as a specialized innovator in CNS therapeutics with a developing global footprint, particularly driven by its lead asset evenamide addressing unmet needs in schizophrenia treatment resistant to standard therapies.
Newron Pharmaceuticals to Participate in June Investor Conferences
Newron Pharmaceuticals S.p.A. (NWPHF) Q4 2025 Earnings Call Transcript
Newron Presents 2025 Financial Results and Provides 2026 Outlook
Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Short Interest in Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Decreases By 23.0%
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week
Newron presents H1 2025 results and provides business update
Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS)
Newron Notes the Publication of New Preclinical Research Suggesting Evenamide Ameliorates Schizophrenia-Related Dysfunction
Edison Issues Report on Newron Pharmaceuticals (NWRN)
Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)
Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference
Newron Pharmaceuticals Reports on Its 2024 Investor Day in New York City
Newron Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A With Evenamide
Newron TRS Study 6 Months' Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry Criteria